Lupin rises on launching authorised generic version of Alinia tablets
Lupin Limited today announced the launch of the authorised generic version of Alinia (Nitazoxanide) tablets, 500 mg of Romark Laboratories, LC Alinia tablets, 500 mg, which are prescribed in the treatment of diarrhoea, caused by Giardia Lamblia or Cryptosporidium Parvum in patients of age 12 years & older.
Reacting to this, the company’s stock today increased by 2.95 per cent and made an intraday high of Rs 1,062.15 per share at 2.14 pm.
Besides, the company reported a net profit of Rs 441.18 crore in Q3FY21. It had reported a loss of Rs 841.36 crore in Q3FY20. The company reported net sales of Rs 3,917.30 crore for Q3FY21, an increase of 5.41 per cent as against the net sales of Rs 3,716.09 crore for Q3FY20.
Lupin is a pharmaceutical company headquartered in Mumbai, India. The company develops and commercialises a wide range of branded and generic formulations, biotechnology products & APIs in over 100 markets over the world.
According to BSE data, the stock traded at a P/E multiple of 40.07 and a price-to-book ratio of 2.60. The stock has a 52-week high and a 52-week low of Rs 1,121.85 and Rs 505, respectively.
At the time of market closing, the stock of the company was trading at Rs 1,055.50, up by 2.31 per cent on BSE.